International journal of cardiology最新文献

{"title":"Cardiovascular comorbidities and risk of in-hospital mortality in acute pancreatitis","authors":"Masashi Hasebe , Chen-Yang Su","doi":"10.1016/j.ijcard.2025.133508","DOIUrl":"10.1016/j.ijcard.2025.133508","url":null,"abstract":"","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"437 ","pages":"Article 133508"},"PeriodicalIF":3.2,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144320875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immediate versus staged complete revascularization in patients presenting with multivessel disease and ST- or non-ST-segment elevation acute coronary syndrome","authors":"Jacob J. Elscot ,&nbsp;Hala Kakar ,&nbsp;Wijnand K. den Dekker ,&nbsp;Johan Bennett ,&nbsp;Manel Sabaté ,&nbsp;Giovanni Esposito ,&nbsp;Eric Boersma ,&nbsp;Eugene McFadden ,&nbsp;Hector M. Garcia-Garcia ,&nbsp;Nicolas M. Van Mieghem ,&nbsp;Roberto Diletti ,&nbsp;on behalf of the BIOVASC investigators","doi":"10.1016/j.ijcard.2025.133496","DOIUrl":"10.1016/j.ijcard.2025.133496","url":null,"abstract":"<div><h3>Background</h3><div>Recent randomized trials have suggested that immediate complete revascularization (ICR) is a viable alternative to staged complete revascularization (SCR) in patients with acute coronary syndrome (ACS) and multivessel disease. However, long-term outcomes comparing ICR with SCR in ST-segment elevation (STE) and non-ST-segment elevation (NSTE) ACS remain unclear.</div></div><div><h3>Methods</h3><div>This study analyzes 2-year follow-up data from the BIOVASC trial, randomizing ACS patients to ICR or SCR. The primary composite endpoint includes all-cause mortality, myocardial infarction, unplanned ischemia-driven revascularization, and cerebrovascular events. Secondary endpoints evaluate these outcomes individually. Cox regression assessed if STE/NSTE-ACS diagnosis influences treatment effect.</div></div><div><h3>Results</h3><div>In 608 STE-ACS patients, the 2-year cumulative incidence of the primary composite endpoint was 10.9 % (ICR) and 11.7 % (SCR) (risk difference [RD] 0.8 %, 95 % confidence interval [CI] -4.3 % to 5.9 %; <em>P</em> = 0.71). In NSTE-ACS, cumulative incidence was 13.5 % (ICR) and 12.8 % (SCR) (RD −0.7 %, 95 % CI -5.1 % to 3.7 %; <em>P</em> = 0.90). No differential effect was observed comparing ICR with SCR between STE- and NSTE-ACS.</div></div><div><h3>Conclusions</h3><div>ICR did not sustain a significant benefit in terms of the primary and secondary outcomes at 2 years follow-up. In addition, no differential effect of ICR versus SCR was observed between STE-ACS and NSTE-ACS after 2 years follow-up. However, there seems to be a late catch-up in the cumulative event rate in patients randomized to ICR.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"437 ","pages":"Article 133496"},"PeriodicalIF":3.2,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Tafamidis on survival in elderly patients: Insights from the Healthcare European Amyloidosis Registry","authors":"Antoine Jobbé-Duval ,&nbsp;Mounira Kharoubi ,&nbsp;Erwan Donal ,&nbsp;Fabrice Bauer ,&nbsp;Amaury Broussier ,&nbsp;Arnaud Bisson ,&nbsp;Océane Bouchot ,&nbsp;Phillipe Charron ,&nbsp;Jérôme Costa ,&nbsp;Pierre-Yves Courand ,&nbsp;Charlotte Dagrenat ,&nbsp;François Delelis ,&nbsp;Jean-Christophe Eicher ,&nbsp;Antoine Fraix ,&nbsp;Barnabas Gellen ,&nbsp;Jean-Pierre Gueffet ,&nbsp;Gilbert Habib ,&nbsp;Jocelyn Inamo ,&nbsp;Julien Jeanneteau ,&nbsp;Damien Legallois ,&nbsp;Thibaud Damy","doi":"10.1016/j.ijcard.2025.133522","DOIUrl":"10.1016/j.ijcard.2025.133522","url":null,"abstract":"<div><h3>Background</h3><div>Cardiac transthyretin amyloidosis (ATTR-CM) is a life-threatening cardiomyopathy. Tafamidis has been demonstrated to be an effective treatment. Our aim was to analyze clinical characteristics and survival of patients with ATTR-CM aged ≥80 years diagnosed after November 2018, treated with tafamidis 80/61 mg, and compare them with a non-treated group diagnosed before that date.</div></div><div><h3>Methods</h3><div>Data from the two groups were extracted from the Healthcare European Amyloidosis Registry (HEAR). Propensity score matching was used to adjust for baseline differences between the groups. Kaplan-Meier survival curves and Cox regression analyses were applied to assess survival outcomes.</div></div><div><h3>Results</h3><div>Out of 1380 patients, 1194 were treated with tafamidis 80/61 mg. Treated patients were significantly less severe at baseline, with a lower occurrence of NYHA class III-IV compared to the untreated group (24 vs. 46 %, <em>p</em> &lt; 0.001). The median NT-proBNP at baseline was lower in the treated group (2330 vs. 4854 pg/ml, p &lt; 0.001), as was the average level of high-sensitivity troponin T (55 vs. 74 ng/ml, p &lt; 0.001), and the interventricular septal thickness (16 vs. 18 mm, p &lt; 0.001). The 3-year survival rate for treated patients was 57 %, and 40 % for untreated patients. In the treated group, the 3-year survival rate was 68 % for patients aged 80–85 years and 58 % for those over 85 years. Survival rates were confirmed after propensity score analyses.</div></div><div><h3>Conclusions</h3><div>This study demonstrates that tafamidis provides significant survival benefits for elderly patients with ATTR-CM, even in those over 85 years old. The findings emphasize the importance of early diagnosis and treatment.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"437 ","pages":"Article 133522"},"PeriodicalIF":3.2,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144314666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cholesterol and Valvular heart disease: Is Lipoprotein(a) the sole culprit?","authors":"Alberto Lorenzatti","doi":"10.1016/j.ijcard.2025.133510","DOIUrl":"10.1016/j.ijcard.2025.133510","url":null,"abstract":"","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"437 ","pages":"Article 133510"},"PeriodicalIF":3.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between change in moderate-to-vigorous physical activity and sedentary behaviour with risk of recurrent cardiovascular events among individuals with coronary heart disease: A prospective cohort study","authors":"Amanda Lönn ,&nbsp;Suzanne J. Carroll ,&nbsp;Theo Niyonsenga ,&nbsp;Adrian Bauman ,&nbsp;Rachel Davey ,&nbsp;Robyn Gallagher ,&nbsp;Nicole Freene","doi":"10.1016/j.ijcard.2025.133513","DOIUrl":"10.1016/j.ijcard.2025.133513","url":null,"abstract":"<div><h3>Background</h3><div>Moderate-to-vigorous physical activity (MVPA) and limiting time in sedentary behaviour (SB) are recommended for the secondary prevention of coronary heart disease (CHD). Little is known about MVPA and SB changes and recurrent cardiovascular events. This study explores the associations between changes in MVPA and SB for recurrent cardiovascular events among individuals with CHD.</div></div><div><h3>Methods</h3><div>Prospective cohort study based on individuals with CHD. MVPA and SB were self-reported, and recurrent cardiovascular events were identified using health registers (2006–2022). Changes in MVPA and SB were categorized as remaining high, decreasing, increasing, and remaining low. Associations were explored using Cox proportional regression models.</div></div><div><h3>Results</h3><div>There were 9430 Australians, 62 % males with a mean age of 70 (SD = 10) years. During the follow-up, with a median time of 4.9 (IQR = 6.1) years, 508 non-fatal cardiac events, 951 total cardiac events, and 2481 major adverse cardiovascular events (MACE) occurred. The risk of recurrent cardiovascular events was 32–39 % lower when MVPA remained high compared to remaining low. An increase in MVPA was associated with a 30 % lower risk of total cardiac events and a 26 % lower risk of MACE, while a decrease was associated with a 16 % lower risk of MACE. Keeping low SB was associated with a 25–29 % lower risk of total cardiac events and MACE than SB remained high. A decrease in SB was associated with a 25 % lower risk of MACE.</div></div><div><h3>Conclusion</h3><div>Supporting individuals with CHD to remain high or improve levels of MVPA and low levels of SB is important in secondary prevention.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"437 ","pages":"Article 133513"},"PeriodicalIF":3.2,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144288711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Difficult-to-treat recurrent pericarditis after SARS-CoV-2 vaccination","authors":"Michele Marchetta ,&nbsp;Rocio I. Lopez ,&nbsp;Michele Golino ,&nbsp;Georgia Thomas ,&nbsp;Antonio Abbate","doi":"10.1016/j.ijcard.2025.133516","DOIUrl":"10.1016/j.ijcard.2025.133516","url":null,"abstract":"<div><h3>Introduction</h3><div>Pericarditis is a recognized but rare complication of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination. While most cases are self-limited, some develop recurrent, difficult-to-treat pericarditis, requiring prolonged management. The exact pathophysiology remains unclear, but vaccine-related immune activation and inflammasome-mediated responses have been implicated.</div></div><div><h3>Methods</h3><div>We reported eight cases of difficult-to-treat pericarditis temporally associated with SARS-CoV-2 vaccination, seen at a single center between October 2021 and January 2025. Diagnosis followed ESC 2015 guidelines, and all patients tested negative for acute SARS-CoV-2 infection.</div></div><div><h3>Results</h3><div>The median age was 56 years, with six receiving Pfizer-BioNTech BNT162b2 and two Moderna mRNA-1273. For six individuals, this was their first episode of pericarditis, whereas two had a prior history of pericarditis. The median time to symptom onset was 14 days. Chest pain was reported by all patients, requiring emergency visits in six cases. Pericardial effusion was present in six patients, with one progressing to tamponade. Cardiac magnetic resonance revealed pericardial late gadolinium enhancement in three of seven patients. All patients received nonsteroidal anti-inflammatory drugs and seven were treated with colchicine. Due to inadequate response to first-line therapies, corticosteroids were administered in all eight cases. Due to persistent symptoms, six patients initiated rilonacept therapy, which led to complete symptom resolution.</div></div><div><h3>Conclusions</h3><div>Pericarditis following SARS-CoV-2 vaccination can evolve into a recurrent, difficult-to-manage inflammatory condition. Effective treatment may require IL-1 blockade to disrupt the autoinflammatory cycle. Prompt recognition and early escalation of therapy are essential to reduce morbidity and prevent complications.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"437 ","pages":"Article 133516"},"PeriodicalIF":3.2,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of pre-transcatheter aortic valve implantation CTA protocols: Optimizing radiation dose and contrast volume","authors":"Giuseppe Tremamunno ,&nbsp;Domenico De Santis ,&nbsp;Curzio Santangeli ,&nbsp;Giovanna G. Bona ,&nbsp;Tiziano Polidori ,&nbsp;Federica Fanelli ,&nbsp;Luca Pugliese ,&nbsp;Carlo Di Donna ,&nbsp;Marta Zerunian ,&nbsp;Chiara Catamo ,&nbsp;Marta Belmonte ,&nbsp;Matteo Casenghi ,&nbsp;Emanuele Barbato ,&nbsp;Andrea Laghi ,&nbsp;Damiano Caruso","doi":"10.1016/j.ijcard.2025.133514","DOIUrl":"10.1016/j.ijcard.2025.133514","url":null,"abstract":"<div><h3>Background</h3><div>To establish the most effective and safe pre-transcatheter aortic valve implantation (TAVI) CT angiography (CTA) protocol by comparing two approaches in terms of image quality, radiation and contrast dose.</div></div><div><h3>Methods</h3><div>Consecutive patients undergoing pre-procedural CTA were prospectively enrolled from January to May 2024. Patients were randomly assigned into two different acquisition protocols: group A underwent an ECG-gated CTA of the thorax followed by a non-gated helical scan of abdomen and pelvis; group B underwent an ECG-gated CTA including only the heart and aortic root, followed by a non-gated helical scan of thorax, abdomen, and pelvis. Objective image analysis was performed by evaluating vascular attenuation, contrast-to-noise ratio (CNR) and signal-to-noise ratio (SNR) in multiple segments. Subjective image analysis was evaluated by two radiologists and radiation and contrast dose were compared between the groups.</div></div><div><h3>Results</h3><div>The final population consisted of 64 patients, 37 in group A and 27 in group B (80.6 ± 5.2 years; 49 males). Group B showed lower radiation dose compared to group A (13.7 ± 1.2 vs 15.7 ± 1.4 mSv; <em>p</em> &lt; 0.001) and lower contrast medium volume (82.9 ± 10.1 vs 90.3 ± 12.0 ml; <em>p</em> = 0.004) while achieving no differences in terms of signal-to-noise ratio, contrast-to-noise ratio and subjective image quality (all <em>p</em> &gt; 0.05). Average vascular attenuation was higher in group A compared to group B (707.1 ± 120.7 vs 633.0 ± 198.6 HU; p &lt; 0.001); however, lumen attenuation at the aortic root was consistent across the two protocols (<em>p</em> = 0.077).</div></div><div><h3>Conclusions</h3><div>Optimization of pre-TAVI CTA protocol results in lower contrast medium volume and radiation dose exposure while maintaining consistent image quality.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"437 ","pages":"Article 133514"},"PeriodicalIF":3.2,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144281089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of a noninvasive device for measuring filling pressure against invasive pulmonary capillary wedge pressure","authors":"Zhibin Lang ,&nbsp;Nicolas Girerd ,&nbsp;Haoran Zhang ,&nbsp;Hongdang Xu ,&nbsp;Lin Qiu ,&nbsp;Liang Zhao ,&nbsp;Shuhui Hou ,&nbsp;Ming Jin ,&nbsp;Hongqi Lin","doi":"10.1016/j.ijcard.2025.133479","DOIUrl":"10.1016/j.ijcard.2025.133479","url":null,"abstract":"<div><h3>Background</h3><div>Intravascular congestion, particularly elevated cardiac filling pressures, is a key component of heart failure and often precedes symptom onset. Early intervention is critical, yet non-invasive tools to detect congestion before symptoms appear are limited.</div></div><div><h3>Objectives</h3><div>This study evaluates the accuracy of a non-invasive filling pressure (NIFP) device in assessing cardiac filling pressure, compared to pulmonary capillary wedge pressure (PCWP) obtained via Swan-Ganz catheterization.</div></div><div><h3>Methods</h3><div>Ninety-eight patients undergoing cardiac surgery had NIFP device measurements immediately before PCWP measurements. Elevated filling pressure was defined by PCWP thresholds of &gt;18 mmHg and ≥ 15 mmHg. Receiver Operating Characteristic (ROC) curves and Pearson correlation coefficients were used for analysis.</div></div><div><h3>Results</h3><div>PCWP measurements were successful in all 98 patients, with 93 (95 %) yielding successful NIFP readings. Using a PCWP &gt;18 mmHg, 14 cases (15 %) were identified with elevated filling pressure. The NIFP device demonstrated an AUROC of 0.84 (<em>p</em> &lt; 0.001), sensitivity of 71.4 %, specificity of 91.1 %, and overall accuracy of 88.2 %. With a PCWP ≥15 mmHg, the AUROC was 0.83, with sensitivity of 66.7 %, specificity of 82.6 %, and overall accuracy of 78.5 %. The Pearson correlation between NIFP and PCWP was 0.55 (<em>p</em> &lt; 0.0001).</div></div><div><h3>Conclusions</h3><div>The NIFP device shows promise as a non-invasive, accurate tool for detecting elevated filling pressures. Its ease of use and potential as a point-of-care tool could have significant implications for heart failure management and early intervention strategies.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"438 ","pages":"Article 133479"},"PeriodicalIF":3.2,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole exome sequencing unravels genetic architecture and its clinical implications in pediatric pulmonary arterial hypertension","authors":"Dai-Ji Jiang ,&nbsp;Yi-Jia Yang ,&nbsp;Yu-Zhen Wang ,&nbsp;Xu Zhang ,&nbsp;Wen-Xiu Chan ,&nbsp;Ting-Ting Yu ,&nbsp;Hao Chen ,&nbsp;Hao Zhang ,&nbsp;Yi Yan ,&nbsp;Li-Jun Fu","doi":"10.1016/j.ijcard.2025.133515","DOIUrl":"10.1016/j.ijcard.2025.133515","url":null,"abstract":"<div><h3>Background</h3><div>Pulmonary arterial hypertension (PAH) is a severe disease with significant genetic predisposition. While genetic architecture and clinical implications in pediatric PAH remain unclear.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed clinical and genetic data from 218 pediatric PAH patients including 115 idiopathic/heritable PAH (IPAH/HPAH) and 103 PAH associated with congenital heart disease (PAH-CHD) admitted to our center between 2011 and 2023.</div></div><div><h3>Results</h3><div>50.0 % of the cohort carried genetic variations, with BMPR2 being the most prevalent (16.5 % in whole and 27.8 % in IPAH/HPAH). Compared to IPAH/HPAH, PAH-CHD showed a distinct mutation profile. Five hotspot mutation sites in 4 PAH-causing genes (BMPR2, ACVRL1, SOX17, KCNK3) were identified, resulting in altered charged amino acid residues or protein truncations. Patients with pathogenic or likely pathogenic (P/LP) mutations in definitive PAH-causing genes (affected mutation carriers) had a higher proportion of high-risk profile, more severe right ventricular enlargement and lower TAPSE, while patients with P/LP mutations in PAH-associated genes showed similar clinical features. Affected mutation carriers also had a poorer prognosis compared to non-carriers and received more aggressive therapeutic interventions. BMPR2 mutation carriers were older at diagnosis and had lower cardiac index compared to other mutation carriers.</div></div><div><h3>Conclusion</h3><div>This study unveiled a different genetic landscape of pediatric PAH in China, and underscored the importance of genetic screening for early risk stratification. A distinct mutation profile in PAH-CHD from IPAH/HPAH patients was found, which warrants further investigation on the identification of predisposing genes for each subpopulation, thus providing new insights into pathogenesis and therapeutic approaches of PAH.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"437 ","pages":"Article 133515"},"PeriodicalIF":3.2,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Interplay between angiography-derived microcirculatory resistance and periprocedural myocardial infarction following rotational atherectomy","authors":"Xi Zhang ,&nbsp;Qing Jin ,&nbsp;Qiang Xue","doi":"10.1016/j.ijcard.2025.133490","DOIUrl":"10.1016/j.ijcard.2025.133490","url":null,"abstract":"","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"437 ","pages":"Article 133490"},"PeriodicalIF":3.2,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144290705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}